Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedSep 21, 2023
DataAggregated Company Financials
Companies50
  • 7D-0.4%
  • 3M-6.6%
  • 1Y10.5%
  • YTD5.8%

In the last week, the Pharma industry is up 2.1%, with Caliway Biopharmaceuticals up 12%. In the last 12 months, the industry was up 12%. As for the next few years, earnings are expected to grow by 42% per annum.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 21 Sep 2023NT$549.4bNT$101.7bNT$9.6b22.2x57.1x5.4x
Sat, 19 Aug 2023NT$543.8bNT$101.7bNT$9.6b21.5x56.5x5.3x
Mon, 17 Jul 2023NT$569.2bNT$98.7bNT$10.1b16.9x56.6x5.8x
Wed, 14 Jun 2023NT$579.4bNT$98.6bNT$10.1b17x57.6x5.9x
Fri, 12 May 2023NT$563.2bNT$92.2bNT$8.6b20.1x65.3x6.1x
Sun, 09 Apr 2023NT$587.2bNT$91.2bNT$8.5b21.1x69.1x6.4x
Tue, 07 Mar 2023NT$565.7bNT$85.0bNT$7.7b24.1x73.7x6.7x
Thu, 02 Feb 2023NT$495.4bNT$84.6bNT$7.9b20x62.8x5.9x
Sat, 31 Dec 2022NT$502.1bNT$84.6bNT$7.9b21.8x63.7x5.9x
Mon, 28 Nov 2022NT$476.9bNT$84.6bNT$7.9b16.3x60.5x5.6x
Wed, 26 Oct 2022NT$382.0bNT$78.9bNT$4.3b16.7x88.3x4.8x
Fri, 23 Sep 2022NT$456.2bNT$78.9bNT$4.3b18.3x105.5x5.8x
Sun, 21 Aug 2022NT$425.3bNT$79.0bNT$4.3b18x97.8x5.4x
Tue, 19 Jul 2022NT$375.6bNT$76.8bNT$4.4b21.5x86x4.9x
Thu, 16 Jun 2022NT$385.2bNT$76.8bNT$4.4b21.3x88.2x5x
Sat, 14 May 2022NT$367.0bNT$76.1bNT$6.3b20.2x58.7x4.8x
Mon, 11 Apr 2022NT$408.2bNT$76.4bNT$6.8b20.9x60.4x5.3x
Wed, 09 Mar 2022NT$385.5bNT$76.5bNT$8.5b19.5x45.3x5x
Fri, 04 Feb 2022NT$379.4bNT$76.7bNT$8.5b18.9x44.8x4.9x
Sun, 02 Jan 2022NT$394.6bNT$76.7bNT$8.5b18.6x46.6x5.1x
Tue, 30 Nov 2021NT$381.5bNT$76.7bNT$8.5b17.8x45.1x5x
Thu, 28 Oct 2021NT$373.6bNT$76.0bNT$10.4b17.2x35.8x4.9x
Sat, 25 Sep 2021NT$357.1bNT$76.0bNT$10.7b18.8x33.3x4.7x
Mon, 23 Aug 2021NT$342.3bNT$76.0bNT$10.7b19.7x31.9x4.5x
Sat, 10 Jul 2021NT$369.1bNT$76.0bNT$10.7b19.1x34.4x4.9x
Fri, 02 Apr 2021NT$363.3bNT$74.2bNT$12.5b19.4x29x4.9x
Mon, 04 Jan 2021NT$343.5bNT$72.1bNT$8.4b18.5x40.7x4.8x
Thu, 08 Oct 2020NT$376.4bNT$71.7bNT$6.5b18.6x58x5.2x
Price to Earnings Ratio

58x


Total Market Cap: NT$376.4bTotal Earnings: NT$6.5bTotal Revenue: NT$71.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 56.5x202120222023
Current Industry PE
  • Investors are relatively neutral on the Taiwanese Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 56.5x.
  • The industry is trading close to its 3-year average PS ratio of 5.3x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 14% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Taiwanese Pharma compare with similar industries?

TW Market-0.29%
Healthcare-0.25%
Pharma-0.39%
Pharma-0.39%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6919 Caliway BiopharmaceuticalsNT$424.0011.9%
+NT$2.8b		n/aPS932.6x
6932 Mercury BiopharmaceuticalNT$20.708.1%
+NT$644.7m		n/aPS3212.8x
6586 CHO PharmaNT$82.502.5%
+NT$368.0m		-54.3%PS252991.1x
6677 Anxo PharmaceuticalNT$51.20-2.3%
NT$326.2m		142.1%PE85.6x
6785 Alar PharmaceuticalsNT$149.503.1%
+NT$256.5m		65.6%PS10651.9x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

6677

NT$51.20

Anxo Pharmaceutical

7D

-2.3%

1Y

142.1%

4105

NT$76.70

TTY Biopharm

7D

-1.9%

1Y

6.2%

6919

NT$424.00

Caliway Biopharmaceuticals

7D

11.9%

1Y

n/a

1795

NT$237.50

Lotus Pharmaceutical

7D

-2.1%

1Y

40.5%

4123

NT$45.55

Center Laboratories

7D

-2.3%

1Y

1.4%

6472

NT$646.00

Bora Pharmaceuticals

7D

-3.9%

1Y

170.7%

1760

NT$101.50

Panion & Bf Biotech

7D

-4.2%

1Y

-31.2%

4166

NT$20.40

Orient Pharma

7D

2.5%

1Y

-5.6%

4746

NT$88.00

Formosa Laboratories

7D

-4.7%

1Y

64.2%

4120

NT$43.35

Orient EuroPharma

7D

3.2%

1Y

26.0%

4119

NT$94.00

SCI Pharmtech

7D

-3.3%

1Y

15.3%

1720

NT$65.20

Standard Chemical & Pharmaceutical

7D

-3.0%

1Y

40.8%

1789

NT$27.25

ScinoPharm Taiwan

7D

0.9%

1Y

8.3%

6785

NT$149.50

Alar Pharmaceuticals

7D

3.1%

1Y

65.6%

6586

NT$82.50

CHO Pharma

7D

2.5%

1Y

-54.3%